Several pivotal trials have demonstrated that PD-1/PD-L1 inhibitors (involving either monotherapy or combination therapy) improve the clinical efficacy of first-line treatment for advanced NSCLC patients without ALK or EGFR mutations (6–8), especially for those with PD-L1 expression ≥ 50% (9, 10). This evidence concerns the gene ALK and non-small cell lung carcinoma.